Cargando…
Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy
Polifeprosan 20 with carmustine (GLIADEL(®)) polymer implant wafer is a biodegradable compound containing 3.85% carmustine (BCNU, bischloroethylnitrosourea) implanted in the brain at the time of planned tumor surgery, which then slowly degrades to release the BCNU chemotherapy directly into the brai...
Autor principal: | Kleinberg, Lawrence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125766/ https://www.ncbi.nlm.nih.gov/pubmed/27920506 http://dx.doi.org/10.2147/PPA.S93020 |
Ejemplares similares
-
Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide
por: Kleinberg, Lawrence
Publicado: (2012) -
Adverse Event with the Use of Carmustine Wafers and Postoperative Radiochemotherapy for the Treatment of High-grade Glioma
por: Salle, Federico, et al.
Publicado: (2018) -
Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
por: Ricciardi, Luca, et al.
Publicado: (2022) -
Carmustine Wafer Implantation at the Era of Standardized Chemoradiation Protocol
por: Roux, Alexandre, et al.
Publicado: (2019) -
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
por: Chowdhary, Sajeel A., et al.
Publicado: (2015)